



Perma-Fix Medical Provides Business Update

Wroclaw – October 3, 2017 – Perma-Fix Medical S.A. (WAR: PFM) today provided a general business update for the second quarter ended June 30, 2017.

Stephen Belcher, Chief Executive Officer of Perma-Fix Medical S.A stated, “We are moving forward with advancing our new process to produce Technetium-99m, the most widely used medical isotope in the world. In particular, we remain focused on preparing our submission to the U.S. Food & Drug Administration. We have been working to further validate our technology through independent contract research companies, which has been successful. Our progress has been somewhat slowed due to the fact the previously announced investor was unable to close on the transaction several months after completion of negotiation of the definitive agreements. As a result, we are seeking funding from alternative sources, and are in active discussions with potential partners to further the technology. In the meantime, we have conducted a number of further tests that will be required for our FDA submission and reinforce the viability and potential of our technology. Based on continued feedback from the industry, both distributors and end-users, we remain confident our new process to produce Technetium-99m provides an unmatched value proposition, while addressing the global need for a safer, more reliable, more cost-effective and uranium-free solution to Tech-99m production. We plan to provide additional updates in the near future.”

About Perma-Fix Medical

Perma-Fix Medical S.A. was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

Justyna Gudaszevska or David K. Waldman
Crescendo Communications Europe Sp. z o.o
Tel: (+48) 693 354 580
Email : pfm@crescendo-ir.com